laf237  (Axon Medchem LLC)

Journal: bioRxiv

Article Title: Biochemical characterization of a Mycobacterium tuberculosis prolyl dipeptidyl peptidase that displays a remarkable thermostability

doi: 10.1101/2022.07.09.499413

Figure Lengend Snippet: hDPP4 inhibitors bind to MtDPP and inhibit its activity. (A) ΔT m of MtDPP after treatment with hDPP4 inhibitors. (B) MtDPP IC 50 inhibition assays with hDPP4 inhibitors depicting inhibition by compounds SYR-322, BI-1356, MK0431 and LAF237. In both, error bars depict standard deviation derived from three experiments in triplicates. TSA melt curve plots can be found in Figure S6D.

Article Snippet: hDPP4 inhibitors SYR-322 (MedChemExpress) , BI-1356 (Macklin) , MK0431 (Aladdin) ( ) and LAF237 (Aladdin) ( ) (Fig. S5) were added separately into enzymatic assays at concentrations ranging from 1×10 −6 to 1 mM and incubated with purified MtDPP in aforementioned enzymatic assay conditions at RT for 15 min prior to the addition of an h-Gly-Pro-βNA substrate.

Techniques: Activity Assay, Inhibition, Standard Deviation, Derivative Assay

Journal: Biomedical Journal

Article Title: Implanted islet mass influences the effects of dipeptidyl peptidase-IV inhibitor LAF237 on transplantation outcomes in diabetic mice

doi: 10.1016/j.bj.2020.10.002

Figure Lengend Snippet: Evolution of nonfasting blood glucose levels after syngeneic transplantation with 150 (A) or 300 (B) islets in each diabetic mouse with (open diamond) and without (solid circle) LAF237 treatment. Values are mean ± SD.

Article Snippet: After islet transplantation, recipients were given daily oral gavage with distilled water (control group) or LAF237 (Axon Medchem, Groningen, Netherlands, 10 mg/kg/day, LAF237 group), for 6 weeks.

Techniques: Transplantation Assay

Journal: Biomedical Journal

Article Title: Implanted islet mass influences the effects of dipeptidyl peptidase-IV inhibitor LAF237 on transplantation outcomes in diabetic mice

doi: 10.1016/j.bj.2020.10.002

Figure Lengend Snippet: Evolution of body weight after syngeneic transplantation with 150 (A) or 300 (B) islets in each diabetic mouse with (open diamond) and without (solid circle) LAF237 treatment. Values are mean ± SD.

Article Snippet: After islet transplantation, recipients were given daily oral gavage with distilled water (control group) or LAF237 (Axon Medchem, Groningen, Netherlands, 10 mg/kg/day, LAF237 group), for 6 weeks.

Techniques: Transplantation Assay

Journal: Biomedical Journal

Article Title: Implanted islet mass influences the effects of dipeptidyl peptidase-IV inhibitor LAF237 on transplantation outcomes in diabetic mice

doi: 10.1016/j.bj.2020.10.002

Figure Lengend Snippet: The intraperitoneal glucose tolerance test at 2, 4 and 6 weeks after syngeneic transplantation with 150 (A) or 300 (B) islets in each diabetic mouse with (open circle) and without (solid circle) LAF237 treatment. Values are mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01 vs. control.

Article Snippet: After islet transplantation, recipients were given daily oral gavage with distilled water (control group) or LAF237 (Axon Medchem, Groningen, Netherlands, 10 mg/kg/day, LAF237 group), for 6 weeks.

Techniques: Transplantation Assay, Control

Journal: Biomedical Journal

Article Title: Implanted islet mass influences the effects of dipeptidyl peptidase-IV inhibitor LAF237 on transplantation outcomes in diabetic mice

doi: 10.1016/j.bj.2020.10.002

Figure Lengend Snippet: The area under the curve of intraperitoneal glucose tolerance test at 2, 4 and 6 weeks after syngeneic transplantation of 150 (A) or 300 (B) islets in each diabetic mouse with (open column) and without (filled column) LAF237 treatment. Values are mean ± SD. ∗ p < 0.05 vs. control.

Article Snippet: After islet transplantation, recipients were given daily oral gavage with distilled water (control group) or LAF237 (Axon Medchem, Groningen, Netherlands, 10 mg/kg/day, LAF237 group), for 6 weeks.

Techniques: Transplantation Assay, Control

Journal: Biomedical Journal

Article Title: Implanted islet mass influences the effects of dipeptidyl peptidase-IV inhibitor LAF237 on transplantation outcomes in diabetic mice

doi: 10.1016/j.bj.2020.10.002

Figure Lengend Snippet: The graft β-cell mass at 6 weeks after syngeneic transplantation of 150 (A) or 300 (B) islets in each diabetic mouse with (open column) and without (filled column) LAF237 treatment. Values are mean ± SD. ∗ p < 0.05 vs. control.

Article Snippet: After islet transplantation, recipients were given daily oral gavage with distilled water (control group) or LAF237 (Axon Medchem, Groningen, Netherlands, 10 mg/kg/day, LAF237 group), for 6 weeks.

Techniques: Transplantation Assay, Control

Journal: Biomedical Journal

Article Title: Implanted islet mass influences the effects of dipeptidyl peptidase-IV inhibitor LAF237 on transplantation outcomes in diabetic mice

doi: 10.1016/j.bj.2020.10.002

Figure Lengend Snippet: Immunohistochemistry with insulin staining (brown color) of the control (A) and LAF237-treated (B) grafts at 6 weeks after syngeneic transplantation of 300 islets. Upper panel: 100X, Lower panel: 400X, Scale bar: 100 μm.

Article Snippet: After islet transplantation, recipients were given daily oral gavage with distilled water (control group) or LAF237 (Axon Medchem, Groningen, Netherlands, 10 mg/kg/day, LAF237 group), for 6 weeks.

Techniques: Immunohistochemistry, Staining, Control, Transplantation Assay